SillaJen: First to use lab-grown human tissue to find best cancer drug dose

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Investors dump Korean biotech HLB stocks on FDA rejection

HLB Co. and its affiliate stocks tumbled on Friday on news that the South Korean biotech group’s highly anticipated new cancer treatment Rivoc...

HLB gets global rights to Chinese liver cancer drug

South Korea’s HLB Therapeutics Co. on Tuesday said its US subsidiary Elevar Therapeutics has acquired the global rights excluding South Kore...

HLB signs with Japan's OSCL for exclusive supply of C-Trelin ingredient

South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has entered into a business agreement with Japan's Osaka Syn...

S.Korea's T&R Biofab secures patent in Japan for 3D-printed liver

South Korea's regenerative medicine company T&R Biofab Co. on Monday said it obtained a patent in Japan for production technology for liver or...

HLB submits new drug application to FDA for Rivoceranib liver cancer drug

HLB Co. announced on May 17 that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Rivo...

HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US

South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...

HLB Cell develops organoid biomaterial based on human normal cells

HLB Cell, a subsidiary of HLB Life Science Co., which specializes in the development of cell therapy products, announced on April 4 that it succeede...

HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China

South Korea's HLB Co. announced on Thursday that the combination therapy of its drug candidate rivoceranib and Jiangsu Hengrui Pharmaceuticals Co., ...

HLB confirms ophthalmic disease treatment in phase 3 clinical trials

South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...

HLB Therapeutics signs contract for COVID vaccine distribution rights

South Korea's pharmaceutical firm HLB Therapeutics Co. said on Monday that it has signed an agreement with the Korea Disease Control and Prevention ...

Retail investors test Celltrion, HLB shares as Korea’s GameStop

Celltrion Inc. and HLB Inc., two leading South Korean biopharmaceutical shares, shot up on Monday as the main bourse’s key index climbed back ...